Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEV2B
- Development stage
- Phase 1
- Lead developer
- Pevion Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PEV2B is a virosome-based vaccine candidate developed by Pevion Biotech for the treatment or prevention of Hepatitis C Virus (HCV) infection. It utilizes a proprietary virosome delivery platform, which consists of synthetic lipid bilayers containing influenza virus surface glycoproteins (hemagglutinin and neuraminidase) but lacking the viral genome. These virosomes serve as both a delivery vehicle and a potent adjuvant. PEV2B specifically carries antigens derived from the HCV envelope glycoproteins E1 and E2. In Phase I clinical trials, it was administered alongside PEV2A (which contains HCV core protein antigens) to evaluate safety and the induction of specific humoral and cellular immune responses against HCV.
- Other names
- HCV virosome vaccine component PEV2B
02
Targets
HCV E2 (Hepatitis C virus envelope glycoprotein E2)HCV E1 (Hepatitis C virus envelope glycoprotein E1)
Beyond the preview
Go deeper on PEV2B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEV2B.